Inventiva Pharma

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )	Digestive System Diseases, Fibrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, fatty liver disease, liver disorder, metabolic dysfunction-associated steatohepatitis, metabolic dysfunction-associated steatotic liver disease	Active, not recruiting	Phase 3	2026-07-02		NCT04849728
Global Research Initiative for Patients Screening on MASH	Body Weight, Digestive System Diseases, Fibrosis, Fibrosis, Liver, Insulin Resistance, Nutritional and Metabolic Diseases, Overweight, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Steatohepatitis, cardiovascular disorder, cirrhosis of liver, diabetes mellitus, endocrine system disorder, fatty liver disease, glucose metabolism disease, hyperinsulinism, hypertensive disorder, liver disorder, metabolic disease, metabolic dysfunction-associated steatohepatitis, metabolic dysfunction-associated steatotic liver disease, nutritional disorder, obesity disorder, overnutrition, type 2 diabetes mellitus, vascular disorder	Recruiting	Not stated	2024-08-01		NCT05651724

Clinical trials